Stay updated on Nivolumab-Daratumumab Combo in Advanced Cancers Clinical Trial

Sign up to get notified when there's something new on the Nivolumab-Daratumumab Combo in Advanced Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab-Daratumumab Combo in Advanced Cancers Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    1%
    Check dated 2025-07-04T04:18:45.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    1.0%
    Check dated 2025-06-19T20:08:09.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    35 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:25:49.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T06:13:47.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T18:02:35.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    The page has undergone significant changes, including the removal of detailed study information regarding the safety and efficacy of Nivolumab combined with Daratumumab for various advanced cancers, while retaining the mention of Janssen Biotech, Inc. as a collaborator and updating the revision number.
    Difference
    7%
    Check dated 2025-04-16T12:44:57.000Z thumbnail image

Stay in the know with updates to Nivolumab-Daratumumab Combo in Advanced Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab-Daratumumab Combo in Advanced Cancers Clinical Trial page.